Skip to main content
. 2014 Sep 6;9(1):282–294. doi: 10.1016/j.molonc.2014.08.012

Figure 7.

Figure 7

HER2 and PTK6 are strongly involved in tumourigenic signalling through interactions with HER1‐3, IGF‐1R or Insulin receptor (IR). The combined inhibition of HER2 and PTK6 strongly reduces the activation of PI3K/Akt, Ras/Raf/MEK/ERK, p38MAPK, STAT 3/5 and Paxillin (Chen et al., 2004) signalling pathways, to decreased activation of transcription factors (TF) and the following gene expression. Inhibited PTK6 does not phosphorylate PTEN and therefore stabilizes this tumour suppressor. Reduced PTK6‐mediated phosphorylation of FoxO3a translocates it to nucleus, induces the expression of the cell cycle inhibitor p27Kip1 and reduces G1‐/S‐phase progression.